Brukinsa 80 mg Capsules
PDF Leaflet Revision Date: 30 January 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of adult patients with WM, MCL, MZL, and CLL/SLL.
Dosage (summary)
320 mg daily (4 capsules) or 160 mg twice daily (2 capsules).
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
May cause fetal harm; avoid breastfeeding during treatment.
Key Drug Interactions
- Strong CYP3A inhibitors
- Moderate CYP3A inhibitors
- Strong CYP3A inducers
Contraindications
- Hypersensitivity to zanubrutinib
Common side effects
- Neutropenia
- Pneumonia
- Fatigue
- Diarrhea
- Rash
Counselling Points
- Take with water, do not chew capsules.
- Avoid grapefruit and Seville oranges.
- Use effective contraception during treatment.
Serious warnings
- Risk of second primary malignancies
- Monitor for atrial fibrillation
- Serious infections
Important Disclaimer
The Brukinsa 80 mg Capsules professional information leaflet below is the property of Beigene South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
